Rezolute, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

LIQUIDITY (Details)

LIQUIDITY (Details) - USD ($) $ in Thousands, shares in Millions			1 Months Ended				3 Months Ended		9 Months Ended		12 Months Ended
	May 04, 2022	May 01, 2022	Jan. 31, 2022	Nov. 30, 2021	Oct. 31, 2021	Dec. 31, 2020	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021
Net loss							$ (11,208)	$ (3,695)	$ (31,637)	$ (14,412)	$ (20,900)
Net cash used in operating activities									(27,506)	(15,211)	(20,400)
Accumulated deficit							(199,775)		(199,775)		(168,138)
Cash and cash equivalents							63,416	$ 31,989	63,416	$ 31,989	41,047
Current liabilities							$ 2,878		2,878		$ 1,968
Net proceeds from the offering				$ 52,300	$ 52,300
Gross proceeds from sale of equity									2,700
Proceeds from warrants issued									10,800
Underwriting discounts and other equity offering costs									4,136
Subsequent event. \| Class B Warrants
Proceeds from warrants issued		$ 41,600
Subsequent event. \| Class C Pre Funded Warrants
Proceeds from warrants issued		$ 12,600
Underwritten Offering
Net proceeds from the offering				47,300	47,300
Registered Direct Offering
Net proceeds from the offering				$ 5,000	$ 5,000
Registered Direct Offering 2022 \| Subsequent event.
Gross proceeds from sale of equity	$ 117,600
Underwriting discounts and other equity offering costs	$ 7,100
Registered Direct Offering 2022 \| Subsequent event. \| Class B Warrants
Warrants issued	10.9
Proceeds from warrants issued	$ 41,600
Securities Purchase Agreement [Member] \| Subsequent event. \| Class C Pre Funded Warrants
Number of shares of common stock called by warrants issued		3.3
Proceeds from warrants issued		$ 11,400
Securities Purchase Agreement [Member] \| Private Placement \| Subsequent event. \| Class C Pre Funded Warrants
Net proceeds from the offering	$ 11,400
Warrants issued	3.3
XOMA (US) LLC [Member] \| Phase 2 Clinical Trial RZ358 \| Xoma License Agreement [Member]
Milestone closing payment			$ 2,000
XOMA (US) LLC [Member] \| Phase 3 Clinical Trial Rz 358 \| Xoma License Agreement [Member] \| Scenario, Plan [Member]
Milestone closing payment			$ 5,000						5,000
ActiveSite Pharmaceuticals, Inc \| Development And License Agreement [Member]
Milestone closing payment						$ 1,000
ActiveSite Pharmaceuticals, Inc \| Phase 2 Clinical Trial RZ402 \| Development And License Agreement [Member] \| Scenario, Plan [Member]
Milestone closing payment									$ 3,000